SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves sharp selloff is drawing attention amid renewed concerns about its heavy debt burden, high borrowing costs and HSBCs bearish assessment of its ability to fund growth. Traders are split between viewing the decline as an overdone move that could fuel a rebound and warning that financing risks could keep pressure on the AI infrastructure provider.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS is drawing attention after its CEOs anniversary message prompted renewed speculation about a potential buyout, alongside anticipation for the final analysis of its Phase 3 REGAL leukemia trial, which requires 80 events and was last reported at 78. Traders disagree on whether the message and prolonged trial timeline signal favorable data or a deal; neither a buyout nor a trial outcome has been confirmed.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as crude swings on fears of Middle East supply disruptions, including reported attacks on shipping and energy infrastructure and heightened Iran-US tensions. Traders are divided between bulls focused on geopolitical supply risks and bears who see peace-deal headlines, disputed reports, or a normalization of flows unwinding the oil premium.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is drawing attention amid a sharp selloff in AI neocloud stocks, as investors weigh financing risks and warnings that some providers may not survive; traders are frustrated that IREN has lagged peers and debate whether the weakness is justified. Some point to the co-CEOs comments that data-center assets carry no debt and customer prepayments help fund GPU costs, while others remain concerned about sector-wide risk and continued selling.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoins rebound toward the $83,000 area has fueled talk of a breakout and possible short squeeze, with bullish traders pointing to resilient buying. Others call the move a temporary bounce and stress that Bitcoin needs to hold key levels above $82,000$83,000 to sustain momentum.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJTs slide to fresh lows, amid concerns about Trumps standing ahead of the midterms and Truth Socials declining appeal, dominates discussion. The community is broadly bearish, citing weak business fundamentals and continued selling, while a few traders see scope for a short-term bounce.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhoods steep selloff and continued weakness dominate discussion, with traders pointing to analyst caution and a risk-off market ahead of earnings. Bears see more downside, while bulls argue the pullback is a buying opportunity and watch for support to hold.

Norwegian Cruise Line Holdings Ltd. engages in the provision of cruise travel services. It offers cruise experiences for travelers with itineraries in Europe, Asia, Australia, New Zealand, South America, Africa, Canada, Bermuda, Caribbean, Alaska and Hawaii. Its brands include Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises. The company was founded in 1966 and is headquartered in Miami, FL.

Norwegian Cruise Line Holdings Ltd

Norwegians reported Q3 outlook increase and reaffirmation of its 2026 outlook, alongside Carnivals strong results lifting cruise shares, are driving renewed interest. Bulls point to resilient bookings and heavy short interest as reasons for optimism, while others remain cautious about fuel costs, debt, and NCLHs lagging performance versus peers; squeeze talk is speculative.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Unconfirmed reports of a possible U.S.Iran deal are driving a sharp, volatile SPY rebound, with traders linking the reports and falling oil prices to the move. The community is split between chasing calls and viewing the rally as a fake-news pump that could fade, citing the lack of official confirmation and conflicting denials.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BCRX is drawing attention for persistent share-price underperformance and widespread frustration with managements shift toward external acquisitions and pipeline investment, which critics fear could add debt and dilution. Bulls point to Orladeyos revenue and upcoming Netherton and Navenibart data, while bearish traders question whether those prospects can restore confidence.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

New Strong Buy Stocks for October 16th

UGP, SCSC, MRKR, SLGL and MEOH have been added to the Zacks Rank #1 (Strong Buy) List on October 16, 2026.

SolGel Technologies (SLGL) Upgraded to Buy: Here's Why

SolGel Technologies (SLGL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

SolGel Technologies (SLGL) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

SolGel Technologies (SLGL) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

MeiraGTx Holdings PLC (MGTX) Q2 Earnings and Revenues Surpass Estimates

MeiraGTx (MGTX) delivered earnings and revenue surprises of +538.46% and +20,637.68%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Metagenomi Therapeutics (MGX) Reports Q2 Loss, Lags Revenue Estimates

Metagenomi Therapeutics (MGX) delivered earnings and revenue surprises of -15.87% and -120.56%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Supernus Pharmaceuticals (SUPN) Matches Q2 Earnings Estimates

Supernus (SUPN) delivered earnings and revenue surprises of 0.00% and +6.84%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Bausch Health (BHC) Q2 Earnings and Revenues Beat Estimates

Bausch (BHC) delivered earnings and revenue surprises of +31.25% and +7.62%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Sol-Gel Technologies Ltd. (SLGL) Reports Q1 Loss, Lags Revenue Estimates

SolGel Technologies (SLGL) delivered earnings and revenue surprises of +28.80% and -88.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Short Interest Up 48.9% in April

Sol-Gel Technologies Ltd. (NASDAQ:SLGL - Get Free Report) saw a significant increase in short interest in the month of April. As of April 15th, there was short interest totaling 18,688 shares, an increase of 48.9% from the March 31st total of 12,551 shares. Based on an average trading volume of...

Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Short Interest Down 31.7% in March

Sol-Gel Technologies Ltd. (NASDAQ:SLGL - Get Free Report) was the target of a large decline in short interest in the month of March. As of March 31st, there was short interest totaling 12,551 shares, a decline of 31.7% from the March 15th total of 18,373 shares. Based on an average daily volume of...

Sol-Gel Technologies Ltd. operates as a clinical-stage dermatology company, which engages in the identification, development, and commercialization of topical dermatological drug products for the treatment of skin diseases. Its products include VERED, TWIN, and SIRS-T. The company was founded by David Avnir and Alon Seri-Levy on October 28, 1997 and is headquartered in Ness Ziona, Israel.

Sol-Gel Technologies Ltd

Sol-Gel Stock Tumbles Over Underwhelming Q1 Earnings: Retail Stays Pessimistic

Equity

Neutral Sentiment

Shares of Sol-Gel Technologies (SLGL) were in the spotlight on Friday morning after the company’s first-quarter (Q1) revenue dipped below Wall Street expectations, and losses came in wider-than-expected.The company, which is focused on developing drugs for skin diseases, <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.sol-gel.com/news-releases/news-release-details/sol-gel-reports-first-quarter-2025-results">reported</a> total revenue of $1 million in the quarter, compared to $0.5 million for the same period in 2024, but below an analyst estimate of $1.2 million, as per FinChat data.Diluted loss per share came in at $3.2, compared to a loss of $2.3 per share for the same period in 2024, and exceeding an estimated loss of $1.2.The company’s research and development expenses soared in the three months through the end of March by 65% year-on-year to $8.8 million.Sol-Gel ended the quarter with $16.9 million in cash, cash equivalents, and deposits. The company expects the cash resources to fund its requirements into the first quarter of 2027.Sol-Gel has two FDA-approved drugs—TWYNEO for treating acne vulgaris in adults and pediatric patients nine years of age and older, and EPSOLAY for treating inflammatory lesions of rosacea in adults.The company is testing a drug candidate for the prevention of new basal cell carcinomas in Gorlin syndrome patients, and another for the treatment of rare skin keratodermas.Earlier this month, Sol-Gel announced a reverse share split at the ratio of 10-for-1 to increase its share price and regain compliance with requirements for continued listing on the exchange.On Stocktwits, retail sentiment around Sol-Gel stayed unchanged within the ‘bearish’ territory over the past 24 hours, coupled with ‘extremely low’ message volume.<figure class="image"><img style="aspect-ratio:624/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_23_at_9_39_02_AM_png_3d341c467c.webp" alt="SLGL's Sentiment Meter and Message Volume as of 9:40 a.m. ET on May 23, 2025 | Source: Stocktwits" width="624" height="63"><figcaption>SLGL's Sentiment Meter and Message Volume as of 9:40 a.m. ET on May 23, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/SLGL">SLGL stock</a> is down by about 25% this year and 5% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/trump-coin-gala-dinner-tells-crypto-backers-biden-made-your-lives-miserable/ch0QkElRbqY">Trump Coin Gala Dinner Highlights: US President Tells Crypto Backers Biden ‘Made Your Lives Miserable,’ Promises Relief</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

The company’s diluted loss per share came in at $3.2, exceeding an estimated loss of $1.2.

Double beat (rev + EPS)

Revenue beat, EPS miss

EPS beat, revenue miss

Double miss

SpaceX ($SPCX) reports earnings after the close today. What do you expect?

Stocktwits

SpaceX

) reports earnings after the close today. What do you expect?

Current Price	$66.25
Prev Close	$64.98
Open	$65.40
Dividend Yield	0.00%
50-Day Moving Average	$71.26
Beta	0.61
Avg. Volume	54,500.81
PE Ratio	-11.51

52-Week High	$97.97
52-Week Low	$28.81
Market Capitalization	$212.74M
EPS (Annual)	-$2.20
Price to Book	4.42
Revenue Per Employee	$692,428.57

Feed

News

Sentiment

Earnings

Fundamentals

Info

SLGL Fundamentals